Read the quarter in context.
A source-linked quarter view: reported numbers, management language, guidance, and the risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹1,545.2 Cr
verified against source
Revenue YoY
65%
reported change
EBITDA
₹355.7 Cr
latest reported figure
Source
screener in
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
Gland Pharma reported consolidated revenue of INR 1,545 crore in Q3 FY24, up 65% YoY, driven by the Cenexi acquisition and strong US base business growth of 17% YoY. EBITDA margin contracted to 23% (vs 31% YoY) due to Cenexi's negative EBITDA of INR 17 crore, impacted by one-time restructuring costs and lower production absorption. Base business EBITDA margin improved to 34% (up 300 bps YoY). PAT declined 17% YoY to INR 192 crore, weighed by higher depreciation from purchase price allocation. US revenue grew 41% YoY, supported by volume growth, new product launches, and Enoxaparin recovery. Cenexi's operational issues persist, with management guiding for EBITDA breakeven in 12-15 months and targeting 10% margins in the medium term. The company expects incremental revenue of EUR 30-40 million from new programs at Cenexi by FY2026. Key risk: Cenexi's operational turnaround may take longer than expected, delaying margin recovery.
Colored figures show movement against the previous available record.
Guidance to track
- Management expects Cenexi to achieve EBITDA breakeven within 12-15 months, with medium-term EBITDA margin target of 10%.
- New programs in tech transfer and approval stages are expected to add EUR 30-40 million to Cenexi's annual revenue in the medium term.
- Ex-Cenexi business targets mid-teens revenue growth over the next 2-3 years, driven by US complex products and CDMO opportunities.
- Cenexi will invest approximately EUR 30 million in new equipment and capacity expansion over the next year.
Risks flagged
- Cenexi faces operational issues including lower productivity, old lines, and regulatory hurdles for product line shifts, which may delay margin recovery.
- Analyst question highlighted that operational issues could delay the EUR 30-40 million incremental revenue from new programs beyond FY2026.
- India revenue declined 7% YoY and remains a low-focus market, with limited growth visibility due to DPCO pricing pressures.
Key quotes
- The growth came from volumes by 8%, and another 3% came from the new launches. But also, Enoxaparin came back, and we are seeing an uptick of volumes.
- The operational efficiency is the current, you know, one of the facilities are, I would say, you know, capacity-wise, it's chockablock. And, we're not able to deliver because of the poor OTIF.
- We have a solid order book of new programs that have been signed and are currently in various stages of tech transfer and approval. With these programs, we anticipate a medium-term incremental increase of EUR 30-40 million on our existing annual revenue base.
Research modules